Relief Therapeutics Holding SA announced that its collaboration partner, ACER Therapeutics Inc. (Acer), has provided an update indicating that the commercial launch activities for OLPRUVA™? (sodium phenylbutyrate) for oral suspension are progressing ahead of schedule.cer now reports the drug will be available in mid-June 2023, subject to additional capital. As a result of ongoing launch readiness efforts, Acer has reported it expects select OLPRUVA™?

dose levels to be available to patients beginning in mid-June 2023 at which time representatives from Acer's patient support service will be available to begin accepting prescriptions. Acer anticipates publishing the OLPRUVA™? list price, or wholesale acquisition cost (WAC), in mid-to-late May.